Oxytocin
Based on 28 publication(s) in Google Scholar
Oxytocin (α-Hypophamine; Oxytocic hormone) is a pleiotropic, hypothalamic peptide known for facilitating parturition, lactation, and prosocial behaviors. Oxytocin can function as a stress-coping molecule with anti-inflammatory, antioxidant, and protective effects especially in the face of adversity or trauma.
For research use only. We do not sell to patients.
- Purity: 99.87%
- CAS No.: 50-56-6
- Formula: C43H66N12O12S2
- Molecular Weight:1007.19
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications Citing Use of MedChemExpress (MCE) Oxytocin
More- Signal Transduct Target Ther. 2023 Jan 2;8(1):3. [Abstract]
- Bioact Mater. 2023 Mar 15:26:337-352. [Abstract]
- Nat Struct Mol Biol. 2022 Mar;29(3):274-281. [Abstract]
- NPJ Biofilms Microbiomes. 2025 Jun 21;11(1):113. [Abstract]
- ACS Appl Mater Interfaces. 2022 May 18;14(19):21822-21835. [Abstract]
- J Headache Pain. 2021 Jul 27;22(1):84. [Abstract]
- Biomed Pharmacother. 2025 Mar:184:117919. [Abstract]
- Transl Psychiatry. 2024 May 25;14(1):208. [Abstract]
- Neurosci Bull. 2025 Aug 6. [Abstract]
- J Ethnopharmacol. 2019 Dec 5:245:112181. [Abstract]
- CNS Neurosci Ther. 2025 Jul;31(7):e70511. [Abstract]
- Front Pharmacol. 2019 Nov 15;10:1380. [Abstract]
- Bioorg Chem. 2025 Feb 1:156:108235. [Abstract]
- Sci Rep. 2020 Oct 2;10(1):16383. [Abstract]
- Metabolites. 2026 Apr 24;16(5):292. [Abstract]
- Psychoneuroendocrinology. 2024 Oct:168:107138. [Abstract]
- Mol Immunol. 2026 Jun:194:94-103. [Abstract]
- Peptides. 2024 Nov 27:171323. [Abstract]
- Organogenesis. 2025 Dec;21(1):2460261. [Abstract]
- Neuroendocrinology. 2023;113(3):343-360. [Abstract]
- Exp Eye Res. 2025 Feb 6:110269. [Abstract]
- Am J Reprod Immunol. 2024 Oct;92(4):e13938. [Abstract]
- Behav Brain Res. 2025 May 8:485:115540. [Abstract]
- SSRN. 2026 Jun 16.
- Northwestern University. 2026.
- Res Sq. 2026 Jan 6.
- SSRN. 2023 Jun 19.
- Evid Based Complement Alternat Med. 2020 May 23;2020:8607931. [Abstract]
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
Histological Imaging/Staining
-
RT-PCR
-
In Vivo Efficacy Study
All Endogenous Metabolite Isoforms
More
Biological Activity
|
Human Endogenous Metabolite |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | EC50 |
10.8 nM
Compound: OT
|
Agonist activity at human oxytocin receptor expressed CHO cells assessed as induction of phospholipase C activity after 15 mins by inositol phosphate accumulation assay
Agonist activity at human oxytocin receptor expressed CHO cells assessed as induction of phospholipase C activity after 15 mins by inositol phosphate accumulation assay
|
[PMID: 21428295] |
| CHO | EC50 |
24.5 nM
Compound: OT
|
Agonist activity at human vasopressin V1b receptor expressed CHO cells assessed as induction of phospholipase C activity after 15 mins by inositol phosphate accumulation assay
Agonist activity at human vasopressin V1b receptor expressed CHO cells assessed as induction of phospholipase C activity after 15 mins by inositol phosphate accumulation assay
|
[PMID: 21428295] |
| CHO | EC50 |
0.04 nM
Compound: 1; OT
|
Agonist activity at human oxytocin receptor expressed in CHO cells assessed as increase in intracellular calcium flux measured for 90 sec by fluo-4 dye based FLIPR assay
Agonist activity at human oxytocin receptor expressed in CHO cells assessed as increase in intracellular calcium flux measured for 90 sec by fluo-4 dye based FLIPR assay
|
[PMID: 27297999] |
| CHO-K1 | EC50 |
2.3 nM
Compound: 1, OT
|
Agonist activity at human oxytocin receptor expressed in CHO-K1 cells after 5 hrs by firefly luciferase reporter gene assay
Agonist activity at human oxytocin receptor expressed in CHO-K1 cells after 5 hrs by firefly luciferase reporter gene assay
|
[PMID: 24874785] |
| COS-1 | EC50 |
15 nM
Compound: 1, OT
|
Activity at oxytocin receptor expressed in COS1 cells assessed as IP-one generation by HTRF assay
Activity at oxytocin receptor expressed in COS1 cells assessed as IP-one generation by HTRF assay
|
[PMID: 21117646] |
| HEK293 | IC50 |
2.7 nM
Compound: I, OT
|
Displacement of [3H]OT from human OT receptor expressed in HEK cells
Displacement of [3H]OT from human OT receptor expressed in HEK cells
|
[PMID: 17316912] |
| HEK293 | EC50 |
10 nM
Compound: 1, OT
|
Agonist activity at human vasopressin V1a expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay
Agonist activity at human vasopressin V1a expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay
|
[PMID: 24874785] |
| HEK293 | EC50 |
240 nM
Compound: 1, OT
|
Agonist activity at human vasopressin V1b expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay
Agonist activity at human vasopressin V1b expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay
|
[PMID: 24874785] |
| HEK293 | EC50 |
7.3 nM
Compound: 1, OT
|
Agonist activity at human vasopressin V2 expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay
Agonist activity at human vasopressin V2 expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay
|
[PMID: 24874785] |
| HEK293 | IC50 |
>10000 nM
Compound: 1, OT
|
Antagonist activity at human vasopressin V1a expressed in AVP-stimulated HEK293 cells after 5 hrs by firefly luciferase reporter gene assay
Antagonist activity at human vasopressin V1a expressed in AVP-stimulated HEK293 cells after 5 hrs by firefly luciferase reporter gene assay
|
[PMID: 24874785] |
| HEK293 | EC50 |
5 nM
Compound: OT
|
Agonist activity at wild type OTR (unknown origin) expressed in HEK293 cells assessed as intracellular calcium flux after 3 mins by fluorescence assay
Agonist activity at wild type OTR (unknown origin) expressed in HEK293 cells assessed as intracellular calcium flux after 3 mins by fluorescence assay
|
[PMID: 25642985] |
| HEK293 | EC50 |
8 nM
Compound: OT
|
Agonist activity at SNAP-tagged oxytocin receptor (unknown origin) expressed in HEK293 cells assessed as intracellular calcium flux after 3 mins by fluorescence assay
Agonist activity at SNAP-tagged oxytocin receptor (unknown origin) expressed in HEK293 cells assessed as intracellular calcium flux after 3 mins by fluorescence assay
|
[PMID: 25642985] |
| HEK293 | EC50 |
2.1 nM
Compound: 1; OT
|
Agonist activity at human oxytocin receptor expressed in HEK293 cells coexpressing Rluc8-tagged Galphaq, N-terminal GFP-tagged Ggamma2 and Gbeta1 protein incubated for 2 mins by Gq protein activation based BRET assay
Agonist activity at human oxytocin receptor expressed in HEK293 cells coexpressing Rluc8-tagged Galphaq, N-terminal GFP-tagged Ggamma2 and Gbeta1 protein incubated for 2 mins by Gq protein activation based BRET assay
|
[PMID: 27420737] |
| HEK293 | EC50 |
0.01 nM
Compound: OT
|
Agonist activity at recombinant human OTR expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method
Agonist activity at recombinant human OTR expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method
|
[PMID: 30896946] |
| HEK293 | EC50 |
0.19 nM
Compound: OT
|
Agonist activity at recombinant human V1a receptor expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method
Agonist activity at recombinant human V1a receptor expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method
|
[PMID: 30896946] |
| HEK293 | EC50 |
0.24 nM
Compound: OT
|
Agonist activity at recombinant human V1b receptor expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method
Agonist activity at recombinant human V1b receptor expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method
|
[PMID: 30896946] |
| HEK293 | EC50 |
0.0046 nM
Compound: OT
|
Agonist activity at human OTR receptor expressed in HEK293 cells assessed as intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method
Agonist activity at human OTR receptor expressed in HEK293 cells assessed as intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method
|
[PMID: 31229420] |
| HEK293 | EC50 |
0.18 nM
Compound: OT
|
Agonist activity at human V1A receptor expressed in HEK293 cells assessed as intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method
Agonist activity at human V1A receptor expressed in HEK293 cells assessed as intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method
|
[PMID: 31229420] |
| HEK293 | EC50 |
0.2 nM
Compound: OT
|
Agonist activity at human V1B receptor expressed in HEK293 cells assessed as intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method
Agonist activity at human V1B receptor expressed in HEK293 cells assessed as intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method
|
[PMID: 31229420] |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Fifty-six male Lister-hooded rats (150-200 g)[1]
-
Dosage:0.1 mg/kg-0.3 mg/kg
-
Administration:Subcutaneous injection; 0.1 mg/kg-0.3 mg/kg; single dose
-
Result:Produced significantly greater hypothermia (at 0.3 mg/kg) than the saline group.
Chemical Information
-
CAS No. 50-56-6
-
Appearance Solid
-
Molecular Weight 1007.19
-
Formula C43H66N12O12S2
-
Color White to off-white
-
Synonyms
α-Hypophamine; Oxytocic hormone
-
Sequence
Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2 (Disulfide bridge:Cys1-Cys6)
-
Sequence Shortening
CYIQNCPLG-NH2 (Disulfide bridge:Cys1-Cys6)
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (28)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
2023 Jan 2;8(1):3. PMID: 36588101
Oxytocin purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2023 Jan 2;8(1):3. [Abstract]
Representative heatmaps showing the duration and location of the shControl and shScgn mice during the 10 min social novelty recognition test. Warmer colors (red) indicate a greater amount of time spent exploring by the mice. shControl: PVN Control-shRNA injection mouse. shScgn: PVN Scgn-shRNA injection mouse. DMSO: 0.1% DMSO administration. Oxytocin acetate: 1 mg/kg Oxytocin administration. S1: a familiar mouse. S2: a novel mouse.
Oxytocin purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2023 Jan 2;8(1):3. [Abstract]
Statistics of marbles burying numbers in shControl and shScgn mice treated with DMSO or Oxytocin acetate.
-
Bioact Mater
Engineered macrophage-biomimetic versatile nanoantidotes for inflammation-targeted therapy against Alzheimer's disease by neurotoxin neutralization and immune recognition suppression. [Abstract]2023 Mar 15:26:337-352. PMID: 36950153 -
Nat Struct Mol Biol
2022 Mar;29(3):274-281. PMID: 35241813 -
NPJ Biofilms Microbiomes
Lactobacillus amylovorus extracellular vesicles mitigate mammary gland ferroptosis via the gut-mammary gland axis. [Abstract]2025 Jun 21;11(1):113. PMID: 40544167 -
ACS Appl Mater Interfaces
Oxytocin Nanogels Inhibit Innate Inflammatory Response for Early Intervention in Alzheimer's Disease. [Abstract]2022 May 18;14(19):21822-21835. PMID: 35510352 -
J Headache Pain
Repeated oxytocin prevents central sensitization by regulating synaptic plasticity via oxytocin receptor in a chronic migraine mouse model. [Abstract]2021 Jul 27;22(1):84. PMID: 34315403
Oxytocin purchased from MedChemExpress. Usage Cited in: J Headache Pain. 2021 Jul 27;22(1):84. [Abstract]
Effect of OT on CGRP and c-fos expression levels. A and C show c-fos, B and D show CGRP. Immunofluorescence staining showed that the number of c-fos-positive cells per FOV and the average fluorescence intensity of CGRP were significantly increased in the NTG + vehicle group compared with the sham group. OT administration significantly reduced the expression of CGRP and c-fos, while these effects were prevented after adding L368,899. Repeated OT (Oxytocin, 20 µg/kg) treatments were quickly administered at 2 µL per nostril or the same volume of saline every two minutes using the tip of the pipette 30 min before NTG and then once daily at the same time point for 11 days.C57BL/6 mice weighing 20 ~ 30 g and 6 ~ 8 weeks of age.
Oxytocin purchased from MedChemExpress. Usage Cited in: J Headache Pain. 2021 Jul 27;22(1):84. [Abstract]
WB data quantification in the mouse trigeminal nucleus caudalis. Repeated OT (Oxytocin, 20 µg/kg) treatments were quickly administered at 2 µL per nostril or the same volume of saline every two minutes using the tip of the pipette 30 min before NTG and then once daily at the same time point for 11 days.C57BL/6 mice weighing 20 ~ 30 g and 6 ~ 8 weeks of age.
Oxytocin purchased from MedChemExpress. Usage Cited in: J Headache Pain. 2021 Jul 27;22(1):84. [Abstract]
OT ameliorated pain sensitization and reduced neuronal activation via OTR. Note that L-368,899 was intraperitoneally injected daily 1 h before OT treatment. The mechanical and thermal pain thresholds of the hind paw and periorbital area were assessed before each NTG injection and on day 11. B, C, D The basal mechanical pain thresholds of the hind paw (B), periorbital area (C), and the thermal pain response of the hind paw (D) were significantly increased in the NTG + OT group compared with the NTG + vehicle group.The pain threshold in the NTG + OT + L368,899 group was markedly decreased compared with the NTG + OT group.Repeated OT (Oxytocin, 20 µg/kg) treatments were quickly administered at 2 µL per nostril or the same volume of saline every two minutes using the tip of the pipette 30 min before NTG and then once daily at the same time point for 11 days.C57BL/6 mice weighing 20 ~ 30 g and 6 ~ 8 weeks of age.
-
Biomed Pharmacother
Bryophyllum pinnatum modulation of signaling pathways relevant for preterm labor in human myometrial cells. [Abstract]2025 Mar:184:117919. PMID: 39983434 -
Transl Psychiatry
Oxytocin attenuates hypothalamic injury-induced cognitive dysfunction by inhibiting hippocampal ERK signaling and Aβ deposition. [Abstract]2024 May 25;14(1):208. PMID: 38796566
Oxytocin purchased from MedChemExpress. Usage Cited in: Transl Psychiatry. 2024 May 25;14(1):208. [Abstract]
Trajectories of PEL-treated group (n = 6), AVP-supplemented group (n = 6), Oxytocin acetate (administered intraperitoneally 1 mg/kg/d for i.p., 50 ng for hippocampal stereotactic injection)-supplemented group (n = 6), and ATO group (n = 6) in the MWM place navigation experiment.
Oxytocin purchased from MedChemExpress. Usage Cited in: Transl Psychiatry. 2024 May 25;14(1):208. [Abstract]
Trajectories of PEL-treated group (n = 6), AVP-supplemented group (n = 6), Oxytocin acetate (administered intraperitoneally 1 mg/kg/d for i.p., 50 ng for hippocampal stereotactic injection)-supplemented group (n = 6), and ATO group (n = 6) in the MWM spatial exploration experiment. The shaded part is the area around the platform, and the activity time of mice in the shaded part is calculated.
Oxytocin purchased from MedChemExpress. Usage Cited in: Transl Psychiatry. 2024 May 25;14(1):208. [Abstract]
Validation of activation of endogenous Oxytocin acetate neurons in mice with PVN Oxytocin acetate neurons activated after PEL surgery.
-
Neurosci Bull
Sex Differences in Pain Contagion Determined by the Balance of Oxytocin and Corticosterone in the Anterior Cingulate Cortex in Rodents. [Abstract]2025 Aug 6. PMID: 40767942 -
J Ethnopharmacol
An experimental study of the anti-dysmenorrhea effect of Chinese herbal medicines used in Jin Gui Yao Lue. [Abstract]2019 Dec 5:245:112181. PMID: 31446072 -
CNS Neurosci Ther
Oxytocin Intervention Mitigates Pathological and Behavioral Impairments in APP/PS1 Mice Subjected to Early Social Isolation. [Abstract]2025 Jul;31(7):e70511. PMID: 40635450 -
Front Pharmacol
Intradermal Injection of Oxytocin Aggravates Chloroquine-Induced Itch Responses via Activating the Vasopressin-1a Receptor/Nitric Oxide Pathway in Mice. [Abstract]2019 Nov 15;10:1380. PMID: 31824317 -
Bioorg Chem
Dehydroepiandrosterone ameliorates primary dysmenorrhea by suppressing the SP1/Hsp90ab1/COX-2 signaling pathway. [Abstract]2025 Feb 1:156:108235. PMID: 39914036 -
Sci Rep
Characterization of five novel vasopressin V2 receptor mutants causing nephrogenic diabetes insipidus reveals a role of tolvaptan for M272R-V2R mutation. [Abstract]2020 Oct 2;10(1):16383. PMID: 33009446 -
Metabolites
Regulation of Human Renal Transporters by Pregnancy-Related Hormones in Primary Proximal Tubular Epithelial Cells. [Abstract]2026 Apr 24;16(5):292. PMID: 42188001 -
Psychoneuroendocrinology
Chronic intranasal oxytocin alleviates cognitive impairment and reverses oxytocin signaling upregulation in MK801-induced mice. [Abstract]2024 Oct:168:107138. PMID: 39068687
Oxytocin purchased from MedChemExpress. Usage Cited in: Psychoneuroendocrinology. 2024 Oct:168:107138. [Abstract]
Expression of OT (Oxytocin) signaling related genes in the hippocampus. RT-PCR analysis were performed on brain tissues from the hippocampus. Con: control; Veh: Vehicle (Saline); RIS: Risperidone; LOT: Low dose (6 μg/kg) of OT; MOT: Medium dose (20 μg/kg) of OT; HOT: High dose (60 μg/kg) of OTAfter 1 week of acclimation, animals in the control group were administered saline (10 ml/kg) and those in the model group were administered MK801 (0.6 mg/kg) through intraperitoneal (i. p.) injections once a day for 21 days. One week after MK801 administration, 6 μg/kg OT (LOT group, n = 10), 20 μg/kg OT (MOT group, n = 10), or 60 μg/kg OT (HOT group, n = 10) was given through the i.n. route twice daily, at 8:30–9:30 AM and 4:00–5:00 PM, for 14 days. Saline (0.2 μL/g) was administered intranasally in the control and vehicle groups. Then, the mice received an i.p. injection of MK801 30 min after OT administration. The mice in the RIS group received an i.p. injection of 0.3 mg/kg RIS once daily for 14 days
Oxytocin purchased from MedChemExpress. Usage Cited in: Psychoneuroendocrinology. 2024 Oct:168:107138. [Abstract]
Effects of chronic intranasal OT (Oxytocin) on levels of spontaneous activity and anxiety-like behaviors in MK801-induced mice Fig. A, the total distance traveled by the mice in the open field test. Fig. 2B, the ratio of distance traveled in the central versus peripheral zone by the mice in the open field test. Con: control; Veh: Vehicle (Saline); RIS: Risperidone; LOT: Low dose (6 μg/kg) of OT; MOT: Medium dose (20 μg/kg) of OT; HOT: High dose (60 μg/kg) of OTAfter 1 week of acclimation, animals in the control group were administered saline (10 ml/kg) and those in the model group were administered MK801 (0.6 mg/kg) through intraperitoneal (i.p.) injections once a day for 21 days. One week after MK801 administration, 6 μg/kg OT (LOT group, n = 10), 20 μg/kg OT (MOT group, n =10), or 60 μg/kg OT (HOT group, n = 10) was giventhrough the i.n. route twice daily, at 8:30–9:30 AM and 4:00–5:00 PM, for 14 days. Saline (0.2 μL/g) was administered intranasally in the control and vehicle groups. Then, the mice received ani.p. injection of MK801 30 min after OT administration. The mice in the RIS group received an i.p. injection of 0.3 mg/kg RIS once daily for 14 days.
-
Mol Immunol
Puerarin and DHEA combination therapy alleviates primary dysmenorrhea via inhibition of the Hsp90ab1/p38/JNK pathway. [Abstract]2026 Jun:194:94-103. PMID: 42030694 -
Peptides
Oxytocin attenuates cardiac hypertrophy by improving cardiac glucose metabolism and regulating OXTR/JAK2/STAT3 axis. [Abstract]2024 Nov 27:171323. PMID: 39613260 -
Organogenesis
Tetramethylpyrazine Confers Protection Against Oxidative Stress and NLRP3-Dependent Pyroptosis in Rats with Endometriosis. [Abstract]2025 Dec;21(1):2460261. PMID: 39967390 -
Neuroendocrinology
Excitatory effects of astrocytic hydrogen sulfide on the electrical activity of oxytocin neurons in the supraoptic nucleus. [Abstract]2023;113(3):343-360. PMID: 36044869 -
Exp Eye Res
Pigment epithelium-derived factor (PEDF) promotes survival and contraction of myoepithelial cells in lacrimal gland. [Abstract]2025 Feb 6:110269. PMID: 39922524 -
Am J Reprod Immunol
2024 Oct;92(4):e13938. PMID: 39403002 -
Behav Brain Res
RAGE/AP-1/OTR signaling pathway in rat hippocampus DG involved in CUS induced depressive-like behaviors. [Abstract]2025 May 8:485:115540. PMID: 40090553 -
-
-
-
-
Evid Based Complement Alternat Med
Guizhi Fuling Capsule Exhibits Antidysmenorrhea Activity by Inhibition of Cyclooxygenase Activity. [Abstract]2020 May 23;2020:8607931. PMID: 32595743
Solvent & Solubility
H2O : ≥ 100 mg/mL (99.29 mM)
DMSO : 100 mg/mL (99.29 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (2.48 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: ≥ 25 mg/mL (24.82 mM); Clear solution
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Purity & Documentation
-
Data Sheet (287 KB)
-
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Korean - KR (480 KB)
- Portuguese - PT (480 KB)
-
Handling Instructions (2659 KB)
References
[1]. Shivali Kohli, et al. Oxytocin attenuates phencyclidine hyperactivity and increases social interaction and nucleus accumben dopamine release in rats. Neuropsychopharmacology. 2019 Jan;44(2):295-305. [Content Brief]
[2]. C Sue Carter, et al. Is Oxytocin "Nature's Medicine"? Pharmacol Rev. 2020 Oct;72(4):829-861. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 0.9929 mL | 4.9643 mL | 9.9286 mL | 24.8215 mL |
| 5 mM | 0.1986 mL | 0.9929 mL | 1.9857 mL | 4.9643 mL | |
| 10 mM | 0.0993 mL | 0.4964 mL | 0.9929 mL | 2.4822 mL | |
| 15 mM | 0.0662 mL | 0.3310 mL | 0.6619 mL | 1.6548 mL | |
| 20 mM | 0.0496 mL | 0.2482 mL | 0.4964 mL | 1.2411 mL | |
| 25 mM | 0.0397 mL | 0.1986 mL | 0.3971 mL | 0.9929 mL | |
| 30 mM | 0.0331 mL | 0.1655 mL | 0.3310 mL | 0.8274 mL | |
| 40 mM | 0.0248 mL | 0.1241 mL | 0.2482 mL | 0.6205 mL | |
| 50 mM | 0.0199 mL | 0.0993 mL | 0.1986 mL | 0.4964 mL | |
| 60 mM | 0.0165 mL | 0.0827 mL | 0.1655 mL | 0.4137 mL | |
| 80 mM | 0.0124 mL | 0.0621 mL | 0.1241 mL | 0.3103 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.